Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of purinostat mesylate vs selinexor in relapsed/refractory DLBCL
ChiCTR2500114877Phase 3Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of purinostat in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Objective response rate by BICR and Overall survival. Started Dec 2025; status: recruiting.
02
Drugs
purinostat
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2500114877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114877.